HB-202 clinical trials
How each study uses HB-202 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HB-202
- 1
Studies by the year they started
3 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Hookipa Biotech GmbH (2) · University of Chicago (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test HB-202.
- Jan 2027TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck CancersPhase 1/2 · University of Chicago
Studies
Open first, then newest update. How each study uses HB-202 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck CancersActive, not recruitingPhase 1/2University of ChicagoNCT05108870Written as HB-202
- A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other CancersCompletedPhase 1/2Hookipa Biotech GmbHNCT04180215Written as HB-202 intravenous administration alternating with HB-201 intravenous administration.
- A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal CancerWithdrawnPhase 2/3Hookipa Biotech GmbHNCT06513884Written as HB-202/HB-201 alternating 2-vector therapy
Codes
What other systems call HB-202 · ClinicalTrials.gg INT017450
- UNII (FDA) O4E1IFK37YHB-202One source FDA
- NCI Thesaurus C173149HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | O4E1IFK37Y | HB-202 | One source FDA |
| NCI Thesaurus | C173149 | HPV 16 E6/E7-encoding Arenavirus Vaccine HB-202 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.